| __timestamp | Alnylam Pharmaceuticals, Inc. | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 10337679 |
| Thursday, January 1, 2015 | 60610000 | 18187286 |
| Friday, January 1, 2016 | 89354000 | 24758063 |
| Sunday, January 1, 2017 | 199365000 | 23666957 |
| Monday, January 1, 2018 | 382359000 | 30099855 |
| Tuesday, January 1, 2019 | 479005000 | 64947625 |
| Wednesday, January 1, 2020 | 588420000 | 186363444 |
| Friday, January 1, 2021 | 620639000 | 272611040 |
| Saturday, January 1, 2022 | 770658000 | 358782000 |
| Sunday, January 1, 2023 | 795646000 | 409864000 |
| Monday, January 1, 2024 | 975526000 |
Unveiling the hidden dimensions of data
In the competitive landscape of biotechnology, understanding the financial strategies of leading companies is crucial. Alnylam Pharmaceuticals and Intra-Cellular Therapies have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Alnylam's SG&A expenses surged by over 1,600%, reflecting its aggressive expansion and market penetration strategies. In contrast, Intra-Cellular Therapies exhibited a more moderate increase of approximately 3,900%, indicating a steady growth approach.
By 2023, Alnylam's SG&A expenses reached nearly double those of Intra-Cellular Therapies, highlighting its larger scale of operations. This divergence in financial strategy underscores the varied paths companies take in the biotech sector to achieve growth and maintain competitiveness. Investors and industry analysts should consider these trends when evaluating the financial health and strategic direction of these companies.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Alnylam Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Merck & Co., Inc. and Alnylam Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Intra-Cellular Therapies, Inc.
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Pharming Group N.V. Trends and Insights
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Mesoblast Limited
Alnylam Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Dynavax Technologies Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Novavax, Inc.
Intra-Cellular Therapies, Inc. and Arrowhead Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Intra-Cellular Therapies, Inc. or Catalyst Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and MannKind Corporation